Cellectar Biosciences

About:

Cellectar Biosciences is a pharmaceutical research company specializing in cancer drugs.

Top Investors: National Cancer Institute, Advantage Capital, Nantahala Capital Management, Venture Investors, Wisconsin Investment Partners

Description:

Cellectar Biosciences, a radiopharmaceutical company, designs and develops products to detect, treat, and monitor various human cancers. Its products include 131I-CLR1404, a compound for cancer therapy. The company's product candidates combine lipid-like molecules and phospholipid ethers analogs with radioisotopes to image or destroy malignant cells. Cellectar Biosciences was formerly known as Cellectar, LLC and changed its name in 2008. The company was founded in 2003 and is based in Madison, Wisconsin.

Total Funding Amount:

$149M

Headquarters Location:

Madison, Wisconsin, United States

Founded Date:

2002-01-01

Contact Email:

business(AT)cellectar.com

Founders:

Jamey Weichert

Number of Employees:

11-50

Last Funding Date:

2023-09-05

IPO Status:

Public

Industries: